Press Releases

Press Releases

  1. Canada First to Receive New Treatment Option for Liver Cancer Patients

  2. PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France

  3. BTG plc: Interim Results 2016

  4. First patient in Malaysia receives TheraSphere™ radioembolisation therapy

  5. BTG and Mirada Medical announce CE Mark Certification for Simplicit90Y dosimetry software in Europe

  6. BTG: settlement of US government investigation into LC Bead®

  7. BTG plc: close period update

  8. BTG Launches βETA™ Radiation Safety Programme, to Reduce the Risk of Radiation Exposure for Healthcare Professionals and Patients

  9. BTG receives Health Canada approval for DC Bead LUMI™

  10. CMS Grants Vistogard® New Technology Add-on Payment Status Effective 1 October 2016

  11. BTG plc: Appointment of Non-executive Director

  12. BTG plc: Annual General Meeting

  13. Varithena® Earns FDA Approval for 30 Day Post-Activation Shelf Life

  14. BTG completes the acquisition of Galil Medical

  15. BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

  16. New study highlights potential cost savings when using yttrium-90 glass microspheres for treatment of hepatocellular carcinoma

  17. BTG plc: Final Results 2016

  18. BTG plc acquires Galil Medical, a leader in cryoablation

  19. BTG plc: Close Period Update

  20. BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma

  21. BTG announces US launch of LC Bead LUMI™, ground-breaking radiopaque embolic bead

  22. BTG International Canada Expands Operations To Directly Sell Interventional Oncology Products

  23. New Data from Largest Prospective Study on CroFab® for Treatment of Copperhead Snake Envenomation

  24. First Patient Treated With LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

  25. First Patients in South Korea Receive TheraSphere® Radioembolisation Treatment

  26. BTG Announces Presentation of New Vistogard® (uridine triacetate) Data at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI)